Evidence map›Paper›PMID 36795307›Full record

ReviewCurrent cardiology reports2023

Frailty and Cardiovascular Mortality: A Narrative Review.

Darae Ko, John A Bostrom, Saadia Qazi, Daniel B Kramer, Dae Hyun Kim, Ariela R Orkaby

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current cardiology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 5 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 5 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Darae Ko *Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1174-7535
John A Bostrom *Section of Cardiovascular Medicine, Boston Medical Center, Boston University School of Medicine, Boston, USA.
Saadia Qazi *Department of Medicine, VA Boston Healthcare System, Boston, MA, USA.
Daniel B KramerRichart A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Dae Hyun KimHinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA, USA.
Ariela R OrkabyDepartment of Medicine, VA Boston Healthcare System, Boston, MA, USA. aorkaby@bwh.harvard.edu.
Beth Israel Deaconess Medical Center · USBoston University · USBrigham and Women's Hospital · US

Funding

Applications of Claims-Based Frailty Index to Advance Evidence for Frailty-Guided Decision-Making - Extension to ADRDR01AG071809 · NIA · HEBREW REHABILITATION CENTER FOR AGED · PI KIM, DAE HYUN · 2021 to 2025
$3.5M
The Trajectories and Clinical Experiences of ICD Therapy (TRACER-ICD) StudyR01AG068141 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KRAMER, DANIEL BRUCE · 2021 to 2025
$3.4M
Prospective Monitoring of Newly Approved Cardiovascular Drugs in Older Adults with FrailtyR01AG062713 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI KIM, DAE HYUN · 2019 to 2022
$2.8M
Mid-Career Mentoring Award For Patient-Oriented Research in Frailty and Health OutcomesK24AG073527 · NIA · HEBREW REHABILITATION CENTER FOR AGED · PI Dae Hyun Kim · 2022 to 2026
$862k
Risk-Guided Atrial Fibrillation Surveillance in Ischemic StrokeK23HL151903 · NHLBI · HEBREW REHABILITATION CENTER FOR AGED · PI KO, DARAE · 2021 to 2025
$822k
Frailty, Statins, and Cardiovascular Disease Burden in Older AdultsR03AG060169 · NIA · HARVARD MEDICAL SCHOOL · PI ORKABY, ARIELA R · 2018 to 2019
$193k
Statins for Primary Prevention of Cardiovascular Disease and FrailtyIK2CX001800 · VA · VA BOSTON HEALTH CARE SYSTEM · PI ORKABY, ARIELA R · 2019 to 2023
–
CSRD VA IK2 CX001800NHLBI NIH HHS K23 HL151903NIA NIH HHS K24 AG073527NIA NIH HHS R01 AG062713NIA NIH HHS R01 AG068141NIA NIH HHS R01 AG071809NIA NIH HHS R03 AG060169
6 · The paper itself

Abstract

purpose of reviewThe goal of the narrative review is to provide an overview of the epidemiology of frailty in cardiovascular disease and cardiovascular mortality and discuss applications of frailty in cardiovascular care of older adults. RECENT

findingsFrailty is highly prevalent in older adults with cardiovascular disease and is a robust, independent predictor of cardiovascular death. There is a growing interest in using frailty to inform management of cardiovascular disease either through pre- or post-treatment prognostication or by delineating treatment heterogeneity in which frailty serves to distinguish patients with differential harms or benefits from a given therapy. Frailty can enable more individualized treatment in older adults with cardiovascular disease. Future studies are needed to standardize frailty assessment across cardiovascular trials and enable implementation of frailty assessment in cardiovascular clinical practice.

Indexed as

Cardiovascular DiseasesFrailtyAgedFrail ElderlyHumansFrailty cardiovascular diseaseMortality

Identifiers

PMID36795307
PMCPMC10130976
OpenAlexW4321004352

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.